GlassScriptPhysician profile
Hasan Dawood
NPI 1831695329
$7,241.93
in general payments reported to CMS, 2019-2025
44 companies · $3,631 in 2025
The $3,631 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $867 · 2024: $2,744 · 2025: $3,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,154 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,154.44 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,310.98 | 2023-2025 | Botox, Ubrelvy, Qulipta |
| Ucb, INC. | $615.10 | 2023-2025 | Briviact, Nayzilam, Rystiggo |
| Axsome Therapeutics, INC. | $373.15 | 2023-2025 | Symbravo, Auvelity, Sunosi |
| Mdd US Operations, LLC | $311.60 | 2023-2025 | Gocovri, Gocovri |
| Pfizer INC. | $310.68 | 2024-2025 | |
| Biogen, INC. | $308.24 | 2024-2025 | Vumerity, Tysabri, Plegridy |
| Otsuka America Pharmaceutical, INC. | $288.88 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $265.26 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Neurelis, INC. | $264.34 | 2023-2025 | Valtoco |
| Lundbeck LLC | $261.75 | 2023-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $248.27 | 2024-2025 | Ingrezza |
| Sk Life Science, INC. | $247.89 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $228.38 | 2023-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $184.79 | 2024-2025 | Hyqvia, Trintellix |
| Scilex Pharmaceuticals INC. | $175.74 | 2023-2025 | Ztlido |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $149.47 | 2024-2025 | Hizentra |
| Catalyst Pharmaceuticals, INC. | $144.52 | 2023-2025 | Fycompa |
| Argenx US, INC. | $142.14 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Alnylam Pharmaceuticals INC. | $124.04 | 2023-2024 | Amvuttra, Onpattro |
| Grifols USA, LLC | $104.52 | 2025 | Gamunex-C |
| Janssen Biotech, INC. | $100.00 | 2025 | |
| Vanda Pharmaceuticals INC. | $89.53 | 2024-2025 | Ponvory |
| Harmony Biosciences LLC | $89.02 | 2023-2025 | Wakix |
| Amneal Pharmaceuticals LLC | $85.56 | 2023-2025 | Crexont, Lyvispah, Rytary |
| Acorda Therapeutics, INC | $81.39 | 2023-2024 | Inbrija |
| Amgen INC. | $74.95 | 2024-2025 | Uplizna |
| Jazz Pharmaceuticals INC. | $66.23 | 2025 | |
| Novartis Pharmaceuticals Corporation | $64.81 | 2023-2024 | |
| Genentech USA, INC. | $61.81 | 2023-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Kyowa Kirin, INC. | $58.75 | 2024-2025 | Nourianz |
| Celgene Corporation | $53.57 | 2023 | Zeposia |
| Emd Serono, INC. | $46.46 | 2025 | |
| Azurity Pharmaceuticals, INC. | $40.00 | 2025 | Horizant |
| Genzyme Corporation | $35.14 | 2025 | |
| Horizon Therapeutics Plc | $33.91 | 2023 | Uplizna |
| Tonix Medicines, INC. | $30.60 | 2025 | Zembrace Symtouch |
| Otter Pharmaceuticals, LLC | $30.00 | 2025 | Sympazan |
| Ani Pharmaceuticals, INC. | $25.00 | 2025 | Purified Cortrophin Gel |
| Idorsia Pharmaceuticals US INC | $22.86 | 2024 | Quviviq |
| Forte Bio-Pharma LLC | $19.76 | 2025 | Tanlor |
| Acadia Pharmaceuticals INC | $19.57 | 2025 | Nuplazid |
| Insightec,INC | $18.60 | 2025 | Exablate |
| Impel Pharmaceuticals INC. | $18.00 | 2023 | Trudhesa |
| C2n Diagnostics, LLC | $16.67 | 2025 | Precivityad2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasan Dawood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.